Each check looks for a different problem. The examples below explain why it matters; they are not contamination findings in Morris Peppy batches. Testing does not make research products suitable for human or animal use.
01 · Purity
What it measures: Measures the target peptide relative to other compounds detected by the method.
Why we test: Synthesis can leave shortened or incomplete peptide chains; storage can produce breakdown products. Those materials may contribute their own biological activity, so an assay response may not come from the intended peptide alone.
A high purity percentage does not establish vial quantity, sterility or the absence of metals. FDA notes that peptide-related impurities can contribute to unwanted immune responses in peptide medicines. This does not predict the effects of a particular research sample. FDA: peptide impurities
02 · Quantity
What it measures: Measures the amount of peptide in the submitted sample.
Why we test: A vial can contain highly pure material but less peptide than its label states. For example, a hypothetical 10 mg vial containing 8 mg would produce a concentration 20% below the intended value when prepared on the assumption that it contains 10 mg.
That error can make a compound appear weaker in an experiment or make results difficult to reproduce. Overfilling can create the opposite error. Purity and quantity answer different questions.
03 · Identity
What it measures: Checks whether the submitted material matches the intended compound.
Why we test: A labeling or material mix-up could leave a vial containing a different peptide. Similar appearance is not evidence of identity: different white powders can look alike.
The wrong compound can act on a different target, produce an unexpected response, or invalidate the experiment. Identity testing checks the match using the reported analytical method; it does not establish clinical safety.
04 · Heavy metals
What it measures: Screens for the metals included in the laboratory’s panel.
Why we test: Raw materials, water or manufacturing equipment are possible sources of metal contamination. Metals such as lead or cadmium would not be ruled out by a peptide purity percentage.
Metal contamination can damage cells and confound toxicity experiments. Human exposure effects depend on the metal, amount and duration; lead can harm the nervous system and kidneys. These are hazard examples, not findings in our batches. WHO: lead exposure
05 · Endotoxins
What it measures: Measures bacterial endotoxins: cell-wall components from Gram-negative bacteria.
Why we test: Bacteria associated with contaminated water or processing surfaces can leave endotoxins behind. Killing the bacteria does not necessarily remove those residues. In an inflammation experiment, the response could therefore come from endotoxin rather than the peptide.
Even very low levels of endotoxin can activate immune cells in cell-based experiments, producing a response that can be mistaken for an effect of the peptide. A sterility result cannot replace an endotoxin result because the two tests look for different things. FDA: pyrogen and endotoxin testing
06 · Fentanyl screening
What it measures: Screens specifically for fentanyl within the method’s detection capability.
Why we test: This is a targeted check for an unintended drug. A material mix-up or cross-contamination is the kind of event a targeted screen can investigate; we are not claiming fentanyl is common in peptides or that it has been found in our products.
Fentanyl exposure can dangerously slow or stop breathing. A negative screen addresses fentanyl within its reporting limit, not every drug, opioid or possible contaminant. CDC/NIOSH: fentanyl effects
07 · Multi-vial conformity
What it measures: Compares purity and peptide-content results across several vials from the same batch.
Why we test: One good result describes one vial. If purity or content varies from vial to vial, a change in an experiment can come from the material itself, which makes results harder to compare across a batch.
Read the individual vial results, not only an average, and any conformity statement the laboratory gives. It is separate from sterility testing, which looks for microbial growth.
08 · Solubility
What it measures: Observes how the sample dissolves in the laboratory’s specified test solution.
Why we test: If some material remains undissolved, the liquid portion may contain less peptide than expected. Taking samples from an uneven suspension can also give inconsistent concentrations.
For example, persistent particles or cloudiness can flag a preparation problem worth investigating. They do not, by themselves, identify contamination: the solvent and test conditions matter. This check is not a general safety test.
09 · Product integrity
What it measures: Checks the submitted vial’s seal integrity using the laboratory’s stated method.
Why we test: A compromised closure can allow outside material or moisture to enter. For example, a damaged seal may no longer maintain the intended barrier, even when the label and contents look normal.
This checks a different failure point from chemical purity. It cannot prove that every shipped vial remains intact, or that a vial remains protected after opening or damage.
10 · Sterility
What it measures: Checks for microbial growth under the conditions of the sterility test.
Why we test: A clean-looking sample can still contain viable microorganisms. The test looks for growth that visual inspection and chemical testing cannot rule out.
Contamination can ruin research: microorganisms can overgrow cultures and distort results. A passing sample test does not guarantee every vial is sterile, and it does not make a research product suitable for human or animal use.
How we use the results
Each newly received batch is independently tested before release, including restocks from the same manufacturer production lot. We review the report and publish the matching batch results. These are ten categories of checks on submitted samples, not ten tests of every vial sold.
Read each finding with its method, units and reporting limits. “Not detected” means below that method’s detection capability; it does not mean an absolute zero. Current batch results remain marked pending until reports are available.
Vanguard: available test methods · FDA: limits of sample sterility testing
Buy independently tested research peptides in the Philippines
Every batch goes through up to 10 independent lab checks, including fentanyl screening and sterility, and its COA is published before release. Same-day delivery in Metro Manila and nationwide shipping.
Browse all research peptides in the Philippines →